A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis

Clinical trial NCT05796245 · COMPLETED

Trial details

NCT number: NCT05796245
Sponsor: Pfizer
Status: COMPLETED
Study type: OBSERVATIONAL

Arthritis, Rheumatoid Colitis, Ulcerative Crohn Disease Psoriasis

Start date: 2023-12-01
Primary completion: 2024-03-14
Enrollment: 2207

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.